1) Alvarado J, Murphy C, Juster R. Trabecular meshwork cellularity in primary open-angle glaucoma and nonglaucomatous normals. Ophthalmology 1984;91:564-79.
2) Rohen JW, Lütjen-Drecoll E, Flügel C, et al. Ultrastructure of the trabecular meshwork in untreated cases of primary open-angle glaucoma. Exp Eye Res 1993;56:683-92.
5) Inoue T, Tanihara H. Rho-associated kinase inhibitors: a novel glaucoma therapy. Prog Retin Eye Res 2013;37:1-12.
6) Thieme H, Nuskovski M, Nass JU, et al. Mediation of calcium-independent contraction in trabecular meshwork through protein kinase C and rho-A. Invest Ophthalmol Vis Sci 2000;41:4240-6.
7) Rao PV, Deng PF, Kumar J, Epstein DL. Modulation of aqueous humor outflow facility by the Rho kinase-specific inhibitor Y-27632. Invest Ophthalmol Vis Sci 2001;42:1029-37.
8) Honjo M, Tanihara H, Inatani M, et al. Effects of rho-associated protein kinase inhibitor Y-27632 on intraocular pressure and outflow facility. Invest Ophthalmol Vis Sci 2001;42:137-44.
9) Novack GD. Rho kinase inhibitors for the treatment of glaucoma. Drugs Future 2013;38:107-13.
14) Honjo M, Tanihara H, Kameda T, et al. Potential role of rho-associated protein kinase inhibitor Y-27632 in glaucoma filtration surgery. Invest Ophthalmol Vis Sci 2007;48:5549-57.
15) Okamura N, Saito M, Mori A, et al. Vasodilator effects of fasudil, a rho-kinase inhibitor, on retinal arterioles in stroke-prone spontaneously hypertensive rats. J Ocul Pharmacol Ther 2007;23:207-12.
16) Satoh K, Fukumoto Y, Shimokawa H. Rho-kinase: important new therapeutic target in cardiovascular diseases. Am J Physiol Heart Circ Physiol 2011;301:H287-96.
17) Koga T, Awai M, Tsutsui J, et al. Rho-associated protein kinase inhibitor, Y-27632, induces alterations in adhesion, contraction and motility in cultured human trabecular meshwork cells. Exp Eye Res 2006;82:362-70.
18) Jain PT, Pento JT, Graves DC. Cell-growth quantitation methods for the evaluation of antiestrogens in human breast cancer cells in culture. J Pharmacol Toxicol Methods 1992;27:203-7.
19) Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983;65:55-63.
20) Ammar DA, Hamweyah KM, Kahook MY. Antioxidants protect trabecular meshwork cells from hydrogen peroxide-induced death. Trans Vis Sci Tech 2012;1:4.
21) Wang H, Joseph JA. Quantifying cellular oxidative stress by dichlorofluorescein assay using microplate reader. Free Radic Biol Med 1999;27:612-6.
22) Vermes I, Haanen C, Steffens-Nakken H, Reutelingsperger C. A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. J Immunol Methods 1995;184:39-51.
23) Polansky JR, Weinreb RN, Baxter JD, Alvarado J. Human trabecular cells. I. Establishment in tissue culture and growth characteristics. Invest Ophthalmol Vis Sci 1979;18:1043-9.
24) Alvarado JA, Wood I, Polansky JR. Human trabecular cells. II. Growth pattern and ultrastructural characteristics. Invest Ophthalmol Vis Sci 1982;23:464-78.
25) Tanihara H, Inoue T, Yamamoto T, et al. Intra-ocular pressure-lowering effects of a rho kinase inhibitor, ripasudil (K-115), over 24 hours in primary open-angle glaucoma and ocular hypertension: a randomized, open-label, crossover study. Acta Ophthalmologica 2015;93:e254-60.
27) Ichikawa M, Yoshida J, Saito K, et al. Differential effects of two ROCK inhibitors, Fasudil and Y-27632, on optic nerve regeneration in adult cats. Brain Res 2008;1201:23-33.
28) Zhou L, Li Y, Yue BY. Oxidative stress affects cytoskeletal structure and cell-matrix interactions in cells from an ocular tissue: the trabecular meshwork. J Cell Physiol 1999;180:182-9.
29) Li G, Luna C, Liton PB, et al. Sustained stress response after oxidative stress in trabecular meshwork cells. Mol Vis 2007;13:2282-8.
30) Sacca SC, Pascotto A, Camicione P, et al. Oxidative DNA damage in the human trabecular meshwork: clinical correlation in patients with primary open-angle glaucoma. Arch Ophthalmol 2005;123:458-63.
31) Ghanem AA, Arafa LF, El-Baz A. Oxidative stress markers in patients with primary open-angle glaucoma. Curr Eye Res 2010;35:295-301.
32) Ferreira SM, Lerner SF, Brunzini R, et al. Oxidative stress markers in aqueous humor of glaucoma patients. Am J Ophthalmol 2004;137:62-9.
33) Majsterek I, Malinowska K, Stanczyk M, et al. Evaluation of oxidative stress markers in pathogenesis of primary open angle glaucoma. Exp Mol Pathol 2011;90:231-7.
34) Luna C, Li G, Liton PB, et al. Resveratrol prevents the expression of glaucoma markers induced by chronic oxidative stress in trabecular meshwork cells. Food Chem Toxicol 2009;47:198-204.
36) Yamamoto K, Maruyama K, Himori N, et al. The Novel Rho Kinase (ROCK) inhibitor K-115: a new candidate drug for neuroprotective treatment in glaucoma. Invest Ophthalmol Vis Sci 2014;55:7126-36.
37) Ding J, Li QY, Wang X, et al. Fasudil protects hippocampal neurons against hypoxia-reoxygenation injury by suppressing microglial inflammatory responses in mice. J Neurochem 2010;114:1619-29.
38) Ding J, Yu JZ, Li QY, et al. Rho kinase inhibitor Fasudil induces neuroprotection and neurogenesis partially through astrocyte-derived G-CSF. Brain Behav Immun 2009;23:1083-8.
39) Del Re DP, Miyamoto S, Brown JH. RhoA/Rho kinase upregulate Bax to activate a mitochondrial death pathway and induce cardiomyocyte apoptosis. J Biol Chem 2007;282:8069-78.
40) Li Q, Liu D, Huang X, Guo L. Fasudil mesylate protects PC12 cells from oxidative stress injury via the Bax-mediated pathway. Cell Mol Neurobiol 2011;31:243-50.